Keith Kwan
Papers
3
Total Citations
636
H-Index
3
About
Dr. Keith Kwan is a leading clinical researcher in head and neck oncology, whose work has fundamentally shaped the treatment landscape for oropharyngeal squamous cell carcinoma (OPSCC). His primary research focus is on comparing curative-intent treatment modalities, specifically radiotherapy and transoral robotic surgery (TORS), to optimize patient outcomes. Dr. Kwan is best known as the principal investigator of the landmark ORATOR trial, a phase 2 randomized study that directly compared these two approaches. The initial results, published in 2019 and cited over 450 times, provided critical, practice-informing data on swallowing function and quality of life. The final five-year outcomes, published in 2024, have further solidified the trial’s impact, offering definitive evidence on survival and toxicity. By leading this rigorous, prospective comparison, Dr. Kwan has addressed a central debate in the field, providing clinicians and patients with essential data to guide shared decision-making. His work has been pivotal in moving beyond anecdotal evidence to establish a high-quality evidence base for the management of HPV-related OPSCC, making him a key figure in modern head and neck cancer care.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3